[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.196.37. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editor's Correspondence
March 28, 2011

Buprenorphine as a Safety Net for Opioid Treatment of Nonmalignant Pain

Author Affiliations

Author Affiliation: Department of Medicine, University of California, San Francisco.

Arch Intern Med. 2011;171(6):596-597. doi:10.1001/archinternmed.2011.83

Dr Katz1 persuasively articulates what many physicians are now thinking as they witness the casualties of chronic noncancer pain (CNCP) opioid therapy first hand and also comments on well-designed studies of adverse consequences now regularly appearing in the pain, pharmacology, and internal medicine literature.

Believers in opioid therapy for CNCP were influenced by a noble impulse to right a series of wrongs. Following decades of opioid excesses, the federal government seized control of opioid prescribing between 1915 and 1920 and severe opiophobia ensued, leading to the neglect of patients, the criminalization of addiction, and the prosecution of physicians. Even as the undertreatment of pain still persists for many populations throughout the world, the pendulum is now swinging back to fears of opioid's hazards in CNCP, particularly when a morphine equivalent dose exceeds a threshold of 100 to 200 mg.

First Page Preview View Large
First page PDF preview
First page PDF preview
×